Clinical Trials

These treatments can reduce symptoms and may stop the tumor from growing for a few months or longer. The usual approach is proven to help patients with your health condition live longer. This trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent).

This study is being done to learn if a new drug, called INCA33890, is safe and if it works well when added to usual treatment. The usual treatment includes bevacizumab and a group of cancer drugs called FOLFOX. FOLFOX has three drugs: oxaliplatin, fluorouracil, and leucovorin or levoleucovorin. Everyone in this study will get bevacizumab and FOLFOX. Participants will be put into one of two groups by chance, like flipping a coin. One group will also get INCA33890. The other group will get a placebo. A placebo looks like the study drug but does not have any medicine in it.

B-ALL is a cancer of the white blood cells. White blood cells are made in the bone marrow, and these cells aid in fighting infections. White blood cells can mature into specialized cells with unique functions. With B-ALL, the white blood cells become abnormal as they mature. These abnormal white blood cells are called blasts. As the blasts grow and divide, they can displace normal, healthy cells. The blasts spread into the bloodstream. Blasts can also spread to the brain, spinal cord, testes, and other places in the body.

Protocol The ROSETTA Lung-202 Trial (CA266-0002) is a Phase 3 study. It looks at how safe and effective a new treatment is for adults with advanced non-small cell lung cancer (NSCLC). This type of cancer has spread to nearby tissue or other parts of the body. The study compares the new treatment with the current standard-of-care (SOC), which is the treatment most commonly used by doctors. It is used as the first treatment for patients whose tumors have high levels of PD-L1, a protein that can stop the immune system from attacking cancer cells. The trial includes patients who cannot have surgery or chemoradiation.

We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced cervical cancer. The usual approach is defined as care most people get for advanced cervical cancer.

This study is testing 2 devices for blocked arteries. One is a new magnesium device that helps your artery heal and then slowly dissolves in about one year. Your body replaces it with natural materials. The other is a regular metal stent that stays in your body forever. Doctors want to learn which one is safer and works better.

SMT112-3005 HARMONi-GI3 The main goal of this study is to test the safety and benefits of the study drug Ivonescimab when it is given with drug called FOLFOX, a mix a platinum-based chemo drug used to treat certain cancers, most notably colorectal cancer. This treatment will be compared to another drug, Avastin, which is also given with FOLFOX, for people receiving their first treatment for cancer. This drug AK-112 is a new drug and has not been approved for use or sale by the U.S. Food and Drug Administration or local health authorities. Avastin is an approved drug.

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

Want to learn more about the effectiveness and safety of the study drug rilvegostomig (also called AZD2936) compared to pembrolizumab, a standard treatment option for lung cancer. The study drug rilvegostomig may help your immune system (body defense) fight your cancer.

This study is to see if a special kind of pacemaker can help people with a certain type of heart problem called HFpEF. This means your heart pumps out blood normally, but it still doesn't work quite right. Some people in the study will get a pacemaker that is set to a heart rate based on their height and a number called LVEF. Others will get a pacemaker that does very little. LVEF is a number that shows how well your heart pumps blood. Doctors get this number from a test called an echocardiogram. This test uses sound waves to take pictures of your heart. The goal is to see if setting the pacemaker to a personalized heart rate helps people feel better.